Inquiry Basket
CAS No.: 246855-74-3
Cat No.: BADC-01782
4.5 
beta-Lac-TEG-N3 is a beta-lactam-based ADC linker with a triethylene glycol spacer and azide group, designed for stable conjugation and enhanced solubility in antibody-drug conjugates. Keywords: ADC linker, beta-lactam linker, TEG spacer, azide linker.
Structure of 246855-74-3
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
beta-Lac-TEG-N3 is a specialized ADC linker intermediate tailored for advanced antibody-drug conjugate (ADC) design and targeted bioconjugation. Featuring a beta-lactam reactive group, a triethylene glycol (TEG) spacer, and a terminal azide, this linker enables selective and bioorthogonal attachment of ADC cytotoxins to antibodies. The TEG spacer enhances hydrophilicity, flexibility, and reduces steric hindrance during conjugation. In ADC linker design, beta-Lac-TEG-N3 preserves antibody structural integrity while allowing efficient site-specific payload attachment, supporting controlled intracellular delivery and improved pharmacokinetic performance.
In payload conjugation applications, beta-Lac-TEG-N3 is compatible with a wide range of ADC cytotoxins, including DNA-damaging agents, microtubule inhibitors, and other potent therapeutic payloads. The beta-lactam group reacts selectively with nucleophilic residues on antibodies, while the azide group enables strain-promoted azide-alkyne cycloaddition (SPAAC) for modular payload installation. The TEG spacer improves solubility, reduces aggregation, and enhances linker flexibility, facilitating homogeneous ADC construction and stable linker-payload conjugates. Researchers can utilize this linker to achieve predictable and reproducible intracellular payload release.
From an application perspective, beta-Lac-TEG-N3 is widely employed in oncology-focused ADC research, protein bioconjugation studies, and innovative targeted drug delivery systems. Its unique combination of beta-lactam reactivity, TEG spacer flexibility, and azide functionality ensures efficient, site-specific conjugation while maintaining antibody function. Incorporating beta-Lac-TEG-N3 into ADC designs allows the creation of stable, customizable linker-payload conjugates capable of delivering cytotoxic agents precisely to tumor cells with enhanced therapeutic potential.
What is beta-Lac-TEG-N3 and its primary application in ADCs?
beta-Lac-TEG-N3 is a non-cleavable linker designed for antibody-drug conjugates, providing stable covalent attachment between payloads and antibodies. Its TEG spacer improves solubility and reduces steric hindrance, enabling efficient conjugation without compromising antibody binding or activity.
12/2/2022
We would like to know how beta-Lac-TEG-N3 influences ADC stability.
The beta-Lac-TEG-N3 linker enhances ADC stability by resisting enzymatic and chemical degradation under physiological conditions. Its non-cleavable design ensures the payload remains attached to the antibody until cellular internalization and lysosomal processing occur.
15/9/2020
We are interested in which conjugation methods are compatible with beta-Lac-TEG-N3.
beta-Lac-TEG-N3 supports bioorthogonal click chemistry reactions, particularly azide-alkyne cycloaddition. This allows precise payload attachment with high efficiency, suitable for site-specific ADC synthesis with minimal impact on antibody function.
5/7/2018
Dear BOC Sciences, what factors should be considered when using beta-Lac-TEG-N3 in ADC development?
When using beta-Lac-TEG-N3, consider solvent compatibility, reaction pH, and molar ratios to optimize conjugation yield. The linker’s hydrophilic TEG segment facilitates solubility, but payload hydrophobicity may require adjustment of formulation conditions.
13/9/2018
Dear team, how should beta-Lac-TEG-N3 be handled to prevent degradation?
beta-Lac-TEG-N3 should be handled under inert atmosphere, protected from moisture and strong light. Use low-temperature storage and minimize exposure to air during preparation. Proper handling maintains its functional azide group for efficient conjugation in ADC development.
9/12/2019
— Dr. Jessica White, Senior Chemist (USA)
beta-Lac-TEG-N3 linker facilitated efficient click chemistry with high solubility and low steric hindrance.
5/7/2018
— Prof. Markus Schmidt, Medicinal Chemist (Germany)
BOC Sciences delivered beta-Lac-TEG-N3 with excellent purity and analytical documentation.
9/12/2019
— Dr. Claire Dubois, ADC Development Scientist (France)
Using this linker, we achieved reproducible ADC yields with minimal side reactions.
13/9/2018
— Mr. Oliver Hughes, R&D Manager (UK)
The TEG spacer enhanced solubility and conjugation efficiency in multiple payload attachments.
12/2/2022
— Dr. Lina Berg, Bioconjugation Specialist (Sweden)
High-quality beta-Lac-TEG-N3 allowed efficient high-throughput screening.
— Ms. Hannah Fischer, Research Scientist (Netherlands)
The linker consistently performed well in bioorthogonal conjugation and intracellular release studies.
15/9/2020
beta-Lac-TEG-N3
Required fields are marked with *
beta-Lac-TEG-N3
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
